		110	A	oproved for a	PTO/\$B/21 (09-04 use through 07/31/2005. OMB 0651-003	
TRANSMITTAL FORM (to be used for all correspondence after Initial filling) Total Number of Pages in This Submission 13 pgs.		Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	official of info 10/664,8 Septemb Gerhard 1621 NWAONI	scilon of information unless it displays a valid OMB control number. 10/664,855 September 22, 2003 Gerhard JAEHNE et al.		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Repty After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	P P P P P P P P P P P P P P P P P P P	Drawing(s) John Street, Stree	n ddress	App of Al Appa (App	r Allowance Communication to TC self Communication to Board poses and Interferences sal Communication to TC sal Communication to TC sal Notice, Brief, Reply Brief) prietary Information us Letter or Enclosure(s) (please Identify w):	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name AVENTIS PHARMACE Signature Dillarann			UKEY, OR	AGENT		
Balaram Gupta						
August 23, 2005 Reg. No. 40,009						
I hereby certify that this correspondence is be sufficient postage as first class mall in an env the date shown below: (USPTO FAX NO. 57	ing facsimil	cosen for Columnstionet lot l	or deposited atents, P.O.	with the Un Box 1450, A	Alexandria, VA 22313-1450 on	
Signature (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 13 pgs.)						
Typed or printed name Maribel Mender				Date	August 23, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sant to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

Docket No.: DEAV2001/0045-US-NP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gerhard Jaehne, et al.

Serial No.: 10/664,855

Filed:

September 22, 2003

Title:

C2-Substituted Indan-1-ols and Their

Derivatives, Processes for Their Preparation and Their Use as

Pharmaceuticals

Examiner:

Nwaonicha, Chukwuma O.

Art Unit:

1621

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile in the Commissioner for Patents, Alexandria, VA 22313, at (571) 273-8300 on

Date of Transmission Mendez
Signature

Date of Transmission

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

SUPPLEMENTAL AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY PURSUANT TO 37 C.F.R. § 1.111

Sir:

This is a supplemental response and Rule 111 Amendment in the above-identified patent application in response to telephone call initiated by the Examiner on August 22, 2005. It is respectfully requested that the following remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 11.

DEAV2001/0045-US-NP2

-1 of 12-